Farhad Hafezi

Call us Now

+41 44 741 8181

Call Back

Request Here

Make Appointment

Come to us @ ELZA

Email Us

info@elza-institute.com

Recommend Us

Thank you!

Telemedicine

Online consultation

ELZA at ESCRS 2022 Milan

Today’s Update from ELZA at ESCRS 2022: Saturday, 17th September

The ELZA team of surgeons and researchers were all in attendance, and today saw Prof. Hafezi give the attending delegates a lecture on “How to treat thin corneas”, where he examined the history of performing corneal cross-linking (CXL) for the treatment of corneal ectasias like keratoconus. He then brought delegates up-to-date on the research that has been performed over the years to improve how thin corneas are cross-linked. Finally, Prof. Hafezi demonstrated the results of the latest thin cornea cross-linking protocol, sub400, developed by ELAZA, which simplifies the process, and can let surgeons, for the first time, cross-link corneas that are as thin as 200 µm.

Read More
Prof. Farhad Hafezi September 17, 2022
ELZA at ESCRS 2022 Milan

Today’s Update from ELZA at ESCRS 2022: Friday, 16th September

The ELZA team of surgeons and researchers were all in attendance, and today saw Prof. Hafezi give the attending delegates a lecture on “How to treat thin corneas”, where he examined the history of performing corneal cross-linking (CXL) for the treatment of corneal ectasias like keratoconus. He then brought delegates up-to-date on the research that has been performed over the years to improve how thin corneas are cross-linked. Finally, Prof. Hafezi demonstrated the results of the latest thin cornea cross-linking protocol, sub400, developed by ELAZA, which simplifies the process, and can let surgeons, for the first time, cross-link corneas that are as thin as 200 µm.

Read More
Prof. Farhad Hafezi September 16, 2022
News: CXL reimbursed in Switzerland

Crosslinking insurance reimbursement in Switzerland

Newsflash: CXL reimbursed in Switzerland

Exactly 20 years after the clinical introduction of cross-linking and after more than 2,000 scientific publications on the subject, corneal cross-linking (CXL) for the treatment of progressive keratoconus has now been included in the Swiss healthcare reimbursement system (the “krankenkasse”).

Read More
Mark Hillen July 4, 2022
Keratoconus and Down Syndeomw - CXL clinical trial paper cover art

Keratoconus and Down Syndrome

People with Down Syndrome have a disproportionately higher risk of developing keratoconus than the general population, and many go on to receive corneal cross-linking (CXL)

Read More
Mark Hillen June 28, 2022
.
.